WO2024259369A1 - Compositions targeting giant cells in blood disorders - Google Patents
Compositions targeting giant cells in blood disorders Download PDFInfo
- Publication number
- WO2024259369A1 WO2024259369A1 PCT/US2024/034194 US2024034194W WO2024259369A1 WO 2024259369 A1 WO2024259369 A1 WO 2024259369A1 US 2024034194 W US2024034194 W US 2024034194W WO 2024259369 A1 WO2024259369 A1 WO 2024259369A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- telomerase
- inhibitor
- antisense oligonucleotide
- giant cell
- subject
- Prior art date
Links
- 208000019838 Blood disease Diseases 0.000 title claims abstract description 33
- 208000014951 hematologic disease Diseases 0.000 title claims abstract description 33
- 208000018706 hematopoietic system disease Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 230000008685 targeting Effects 0.000 title claims abstract description 9
- 108010017842 Telomerase Proteins 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 59
- 210000004027 cell Anatomy 0.000 claims description 45
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 39
- 210000002540 macrophage Anatomy 0.000 claims description 25
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims description 20
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 19
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 18
- 150000003384 small molecules Chemical group 0.000 claims description 17
- 229950004291 imetelstat Drugs 0.000 claims description 15
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical group N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 claims description 13
- 229940123582 Telomerase inhibitor Drugs 0.000 claims description 9
- 239000003277 telomerase inhibitor Substances 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000562 conjugate Substances 0.000 description 4
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010065163 Clonal evolution Diseases 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- Blood Disorders and “Blood Disorder” here refer specifically to Myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML).
- MDS Myelodysplastic syndromes
- AML Acute myeloid leukemia
- Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly formed or do not function properly. This syndrome can be caused by inherited changes in the Runx-related transcription factor 1 (RU NXI ) gene, which control the development of blood cells. Acute myeloid leukemia is a cancer of the blood and bone marrow. MDS and AML are both considered “Blood Disorders”. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are incurable diseases except for ⁇ 10% individuals who can be successfully treated with allogeneic transplantation (1, 2). Most therapies fail to produce sustained responses because of rapid clonal evolution and appearance of disease resistance (3, 4).
- MDS Myelodysplastic syndromes
- AML acute myeloid leukemia
- Telomerase is an enzyme involved in the maintenance of telomers which are repeated sequences that cap the ends of chromosomes.
- CD 163 is a molecule that is primarily expressed on the surfaces of macrophages. It regulates inflammatory responses and has a role in iron metabolism and wound healing.
- Giant cells are cells often formed by the fusion of multiple cells, including a macrophage/monocyte cell, which can be associated with tumors. Giant cells can range in size upward from 40 microns.
- a first aspect of the invention is directed to a method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that inhibits telomerase activity, or inhibits expression of, telomerase in a Giant Cell.
- the Blood Disorder may be myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- a related aspect of the invention further comprises detecting or isolating a Giant Cell from the subject with a Blood Disorder prior to administering the drug or biological product, wherein the Giant Cell expresses telomerase.
- a related aspect is directed to a composition for treating a Blood Disorder comprising a drug or biological product that inhibits telomerase activity, or inhibits expression of, telomerase in a Giant Cell.
- drugs or biological agents may comprise telomerase-specific antisense oligonucleotide, such as Imetelstat, and/or a small molecule inhibitor of telomerase such as BIRBI 52 or comprising antibody drug conjugates targeted to Giant Cells expressing telomerase.
- Another aspect of the invention is directed to a method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that binds to a macrophage marker on a Giant Cell and inhibits telomerase activity.
- the Blood Disorder includes myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- a related aspect is directed to a composition for treating a Blood Disorder comprising a drug or biological product that binds to the macrophage marker CD 163.
- the composition may comprise a conjugate drug antibody such as a monoclonal antibody or other ligand that targets a macrophage marker on a Giant Cell and a second active component or moiety inhibiting telomerase activity.
- Another aspect of the invention is directed to a combination of therapies or detection methods which target expression of telomerase on Giant Cells as well as expression of macrophage markers such as CD 163 on Giant Cells.
- FIGS. 1A and IB show Giant Cells from MDS patients showing CDI63 expression. Giemsa stained (left) and CD 163 stained (right) giant cell isolated from peripheral blood of a patient with MDS.
- FIG. 1A shows Giemsa staining.
- FIG. IB shows staining for CD163.
- FIGS. 2A-2D show that giant cells from MDS patients show telomerase expression.
- Giant cells show strong positive signals for hTERT (FIGS. 2A, 2B and 2C) whereas small cells show weak signals for human telomerase reverse transcriptase (hTERT) (FIG. 2D).
- FIG. 3 shows a schematic representation of CD 163 targeting-Imetelstat conjugate ADC.
- the subject matter disclosed herein provides a method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject a composition targeting Giant Cells expressing telomerase.
- the Blood Disorder is Myelodysplastic syndromes (MDS).
- the Blood Disorder is acute myeloid leukemia (AML).
- MDS myelodysplastic syndromes
- AML acute myeloid leukemia
- GCs circulating giant cells
- ISET highly sensitive sizebased method
- GC cells have a size of 40 microns or larger.
- the inventors found GC in 46/99 MDS tested patients and in 1 1/66 healthy controls through the analysis of, on average, 9 ml of blood. Overall, 408 GC have been identified in MDS patients and 28 GC in controls. GC could be characterized using immunomorphological analyses. 69.4% of GC in MDS patients scored positive for macrophage specific antibodies (CD163, CDl lb, CD68,) (FIGS. 1A-1B). Interestingly it was also found that 74.4% of GC were strongly positive with the telomerase specific antibody (FIGS. 2A-D). Furthermore, 97.4% of GC scored positive for CD61 and 54% of GC were positive for Runx2. These results show for the first time that the detection of GC in the peripheral blood of MDS patients is not a rare event and demonstrate the clinical relevance of GC pathogenesis in patients with MDS.
- telomerase function involves targeting the telomerase itself with oligonucleotide inhibitors such as Imetelstat (lipidated 13-mer thiophosphoramidate oligonucleotide complementary to the TERC template region) in AML or MDS.
- Imetelstat lipidated 13-mer thiophosphoramidate oligonucleotide complementary to the TERC template region
- MDS M-display oligonucleotide inhibitors
- the inventors consider a conjugate drug compound comprising Imetelstat or other telomerase-specific antisense oligonucleotides (11) with antibodies binding to CD 163 or other macrophage markers.
- FIG. 3 shows a schematic representation of CD 163 targeting-Imetelstat conjugate ADC in Blood Disorders.
- a small molecule inhibitor BIBRI 532 (non-competitive small molecule inhibitor of telomerase), can also target telomerase in Blood Disorders.
- GC are characterized by the presence of macrophage markers, including CD 163, and high telomerase expression, this offers a unique opportunity to specifically target GC and spare normal macrophages that show' no or low' telomerase activity. Except for B/plasma cells, the majority of the terminally differentiated cell types in the body do not show 7 telomerase expression.
- This disclosure provides a method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject a composition targeting telomerase expression in a Giant Cell of the Blood Disorder expressing CD 163; wherein the Blood Disorder is Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- MDS Myelodysplastic syndrome
- AML acute myeloid leukemia
- the subject is in need of treatment of MDS. In another embodiment of this method, the subject is in need of treatment for AML.
- the composition comprises a telomerase-specific antisense oligonucleotide. In some embodiments, the telomerase-specific antisense oligonucleotide is Imetelstat.
- the composition comprises a molecule specific for an antigen on the Giant Cell, wherein the antigen comprises a macrophage marker, and wherein the molecule is conjugated to a telomerase inhibitor.
- the macrophage marker is CD 163.
- the telomerase inhibitor is a telomerase-specific antisense oligonucleotide.
- the telomerase-specific antisense oligonucleotide is Imetelstat.
- the telomerase inhibitor is a small molecule inhibitor, BIBRI 532.
- the molecule is an antibody specific for a macrophage marker.
- the molecule is an antibody specific for CD 163.
- the antibody may be a monoclonal antibody or an antigen-binding fragment of an antibody.
- the composition comprises a small molecule inhibitor of the telomerase such as, but not limited to, BIBRI532.
- a method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that inhibits telomerase activity, or inhibits expression of telomerase in a Giant Cell.
- the drug or biological product comprises a telomerase-specific antisense oligonucleotide.
- the telomerase-specific antisense oligonucleotide is Imetelstat.
- the drug or biological product comprises a small molecule inhibitor of telomerase.
- the drug or biological product comprises BIRB1532.
- the drug or biological product comprises an antibody or antibody conjugate that comprises a telomerase-specific antisense oligonucleotide such as Imetelstat and/or a small molecule inhibitor of telomerase such as BIRB1532.
- any one of embodiments 1-9 further comprising detecting or isolating a Giant Cell from the subject with MDS or AML prior to administering the drug or biological product; wherein the Giant Cell expresses telomerase.
- composition of embodiment 12 that comprises a telomerase-specific antisense oligonucleotide, such as Imetelstat, and/or a small molecule inhibitor of telomerase such as BIRB152
- composition of embodiment 12 that comprises an antibody conjugate comprising an antibody that binds to CD 163 on a Giant Cell and a telomerase-specific antisense oligonucleotide, such as Imetelstat, and/or a small molecule inhibitor of telomerase such as BIRBI 52.
- composition of embodiment 14 that comprises a monoclonal antibody that binds to a Giant Cell from a MDS or AML patient expressing telomerase.
- a method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that binds to a macrophage marker in or on a Giant Cell.
- the Blood Disorder is myelodysplastic syndrome (MDS).
- MDS myelodysplastic syndrome
- AML acute myeloid leukemia
- the composition comprises an antibody or other ligand that binds to the macrophage marker.
- the method of embodiment 20, wherein the Giant Cell is detected or isolated from the blood of the subject with MDS or AML.
- the method of embodiment 20, wherein the drug or biological product is an antibody that binds to a macrophage marker on the Giant Cell.
- the method embodiment 20, wherein the macrophage marker on the Giant Cell is
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The subject matter disclosed herein relates to a method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject with a Blood Disorder a composition targeting a telomerase in a Giant Cell of the Disorder.
Description
COMPOSITIONS TARGETING GIANT CELLS IN BLOOD DISORDERS
CROSS-REFERENCE TO A RELATED APPLICATION
This application claims priority to U.S. Provisional Application No. 63/508,087, filed June 14, 2023 which is incorporated by reference for all purposes.
This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights.
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosure of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described herein.
BACKGROUND
The terms “Blood Disorders” and “Blood Disorder” here refer specifically to Myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML).
Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly formed or do not function properly. This syndrome can be caused by inherited changes in the Runx-related transcription factor 1 (RU NXI ) gene, which control the development of blood cells. Acute myeloid leukemia is a cancer of the blood and bone marrow. MDS and AML are both considered “Blood Disorders”.
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are incurable diseases except for <10% individuals who can be successfully treated with allogeneic transplantation (1, 2). Most therapies fail to produce sustained responses because of rapid clonal evolution and appearance of disease resistance (3, 4).
Telomerase is an enzyme involved in the maintenance of telomers which are repeated sequences that cap the ends of chromosomes.
CD 163 is a molecule that is primarily expressed on the surfaces of macrophages. It regulates inflammatory responses and has a role in iron metabolism and wound healing.
Giant cells are cells often formed by the fusion of multiple cells, including a macrophage/monocyte cell, which can be associated with tumors. Giant cells can range in size upward from 40 microns.
SUMMARY OF THE INVENTION
A first aspect of the invention is directed to a method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that inhibits telomerase activity, or inhibits expression of, telomerase in a Giant Cell. The Blood Disorder may be myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
A related aspect of the invention further comprises detecting or isolating a Giant Cell from the subject with a Blood Disorder prior to administering the drug or biological product, wherein the Giant Cell expresses telomerase.
A related aspect is directed to a composition for treating a Blood Disorder comprising a drug or biological product that inhibits telomerase activity, or inhibits expression of, telomerase in a Giant Cell. Such drugs or biological agents may comprise telomerase-specific antisense oligonucleotide, such as Imetelstat, and/or a small molecule inhibitor of telomerase
such as BIRBI 52 or comprising antibody drug conjugates targeted to Giant Cells expressing telomerase.
Another aspect of the invention is directed to a method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that binds to a macrophage marker on a Giant Cell and inhibits telomerase activity. The Blood Disorder includes myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
A related aspect is directed to a composition for treating a Blood Disorder comprising a drug or biological product that binds to the macrophage marker CD 163. The composition may comprise a conjugate drug antibody such as a monoclonal antibody or other ligand that targets a macrophage marker on a Giant Cell and a second active component or moiety inhibiting telomerase activity.
Another aspect of the invention is directed to a combination of therapies or detection methods which target expression of telomerase on Giant Cells as well as expression of macrophage markers such as CD 163 on Giant Cells.
BRIEF DESCRIPTION OF FIGURES
This application fde contains at least one drawing executed in color. Copies of this patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
FIGS. 1A and IB show Giant Cells from MDS patients showing CDI63 expression. Giemsa stained (left) and CD 163 stained (right) giant cell isolated from peripheral blood of a patient with MDS.
FIG. 1A shows Giemsa staining.
FIG. IB shows staining for CD163.
FIGS. 2A-2D show that giant cells from MDS patients show telomerase expression.
Giant cells show strong positive signals for hTERT (FIGS. 2A, 2B and 2C) whereas small cells show weak signals for human telomerase reverse transcriptase (hTERT) (FIG. 2D).
FIG. 3 shows a schematic representation of CD 163 targeting-Imetelstat conjugate ADC.
DETAILED DESCRIPTION OF THE INVENTION
In certain aspects, the subject matter disclosed herein provides a method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject a composition targeting Giant Cells expressing telomerase. In some embodiments, the Blood Disorder is Myelodysplastic syndromes (MDS). In some embodiments, the Blood Disorder is acute myeloid leukemia (AML).
As mentioned above, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are incurable diseases except for < 10% individuals who can be successfiilly treated with allogeneic transplantation. Most therapies fail to produce sustained responses because of rapid clonal evolution and appearance of disease resistance.
In view of the failure and limitations of past treatments, the inventors searched for the presence of circulating giant cells (GCs) in patients with MDS using a highly sensitive sizebased method (ISET) commonly used to isolate circulating tumor cells.
GC cells have a size of 40 microns or larger. The inventors found GC in 46/99 MDS tested patients and in 1 1/66 healthy controls through the analysis of, on average, 9 ml of blood. Overall, 408 GC have been identified in MDS patients and 28 GC in controls. GC could be characterized using immunomorphological analyses. 69.4% of GC in MDS patients scored positive for macrophage specific antibodies (CD163, CDl lb, CD68,) (FIGS. 1A-1B). Interestingly it was also found that 74.4% of GC were strongly positive with the telomerase specific antibody (FIGS. 2A-D). Furthermore, 97.4% of GC scored positive for CD61 and 54%
of GC were positive for Runx2. These results show for the first time that the detection of GC in the peripheral blood of MDS patients is not a rare event and demonstrate the clinical relevance of GC pathogenesis in patients with MDS.
The inventors considered several approaches to targeting telomerase function. Some direct approaches involve targeting the telomerase itself with oligonucleotide inhibitors such as Imetelstat (lipidated 13-mer thiophosphoramidate oligonucleotide complementary to the TERC template region) in AML or MDS. To achieve specific targeting, the inventors consider a conjugate drug compound comprising Imetelstat or other telomerase-specific antisense oligonucleotides (11) with antibodies binding to CD 163 or other macrophage markers.
FIG. 3 shows a schematic representation of CD 163 targeting-Imetelstat conjugate ADC in Blood Disorders. A small molecule inhibitor, BIBRI 532 (non-competitive small molecule inhibitor of telomerase), can also target telomerase in Blood Disorders.
Since GC are characterized by the presence of macrophage markers, including CD 163, and high telomerase expression, this offers a unique opportunity to specifically target GC and spare normal macrophages that show' no or low' telomerase activity. Except for B/plasma cells, the majority of the terminally differentiated cell types in the body do not show7 telomerase expression.
Embodiments of the invention include the following:
This disclosure provides a method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject a composition targeting telomerase expression in a Giant Cell of the Blood Disorder expressing CD 163; wherein the Blood Disorder is Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
In one embodiment the subject is in need of treatment of MDS. In another embodiment of this method, the subject is in need of treatment for AML.
In some embodiments, the composition comprises a telomerase-specific antisense oligonucleotide. In some embodiments, the telomerase-specific antisense oligonucleotide is Imetelstat.
In some embodiments, the composition comprises a molecule specific for an antigen on the Giant Cell, wherein the antigen comprises a macrophage marker, and wherein the molecule is conjugated to a telomerase inhibitor.
In some embodiments, the macrophage marker is CD 163. In some embodiments, the telomerase inhibitor is a telomerase-specific antisense oligonucleotide.
In some embodiments, the telomerase-specific antisense oligonucleotide is Imetelstat. In some embodiments, the telomerase inhibitor is a small molecule inhibitor, BIBRI 532.
In some embodiments, the molecule is an antibody specific for a macrophage marker.
In some embodiments, the molecule is an antibody specific for CD 163. The antibody may be a monoclonal antibody or an antigen-binding fragment of an antibody.
In some embodiments, the composition comprises a small molecule inhibitor of the telomerase such as, but not limited to, BIBRI532.
Other embodiments of the invention include but are not limited to those which follow.
1 . A method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that inhibits telomerase activity, or inhibits expression of telomerase in a Giant Cell.
2. The method of embodiment 1 , wherein the Giant Cell from the subject expresses telomerase
3. The method of embodiment 1 , wherein the Blood Disorder is myelodysplastic syndrome (MDS).
4. The method of embodiment 1 , wherein the Blood Disorder is acute myeloid leukemia
(AML).
The method of embodiment 1 , wherein the drug or biological product comprises a telomerase-specific antisense oligonucleotide. The method of embodiment 1 , wherein the telomerase-specific antisense oligonucleotide is Imetelstat. The method of embodiment 1 , wherein the drug or biological product comprises a small molecule inhibitor of telomerase. The method of embodiment 1 , wherein the drug or biological product comprises BIRB1532. The method of embodiment 1 , wherein the drug or biological product comprises an antibody or antibody conjugate that comprises a telomerase-specific antisense oligonucleotide such as Imetelstat and/or a small molecule inhibitor of telomerase such as BIRB1532. The method of any one of embodiments 1-9, further comprising detecting or isolating a Giant Cell from the subject with MDS or AML prior to administering the drug or biological product; wherein the Giant Cell expresses telomerase. The method of embodiment 10, wherein the Giant Cell is detected or isolated from the blood of the subject with MDS or AML A composition for treating a Blood Disorder comprising a drug or biological product that inhibits telomerase activity, or inhibits expression of telomerase in a Giant Cell. The composition of embodiment 12 that comprises a telomerase-specific antisense oligonucleotide, such as Imetelstat, and/or a small molecule inhibitor of telomerase such as BIRB152 The composition of embodiment 12 that comprises an antibody conjugate comprising an antibody that binds to CD 163 on a Giant Cell and a telomerase-specific antisense
oligonucleotide, such as Imetelstat, and/or a small molecule inhibitor of telomerase such as BIRBI 52. The composition of embodiment 14 that comprises a monoclonal antibody that binds to a Giant Cell from a MDS or AML patient expressing telomerase. A method of treating a Blood Disorder in a subject comprising administering to a subject in need thereof a drug or biological product that binds to a macrophage marker in or on a Giant Cell. The method of embodiment 16, wherein the Blood Disorder is myelodysplastic syndrome (MDS). The method of embodiment 16, wherein the Blood Disorder is acute myeloid leukemia (AML). The method of embodiment 16, wherein the composition comprises an antibody or other ligand that binds to the macrophage marker. The method of any one of embodiments 16-19, further comprising detecting or isolating a Giant Cell from the subject with MDS or AML prior to administering the drug or biological product; wherein the Giant Cell expresses a macrophage marker and telomerase. The method of embodiment 20, wherein the Giant Cell is detected or isolated from the blood of the subject with MDS or AML. The method of embodiment 20, wherein the drug or biological product is an antibody that binds to a macrophage marker on the Giant Cell. The method embodiment 20, wherein the macrophage marker on the Giant Cell is
CD163.
24. The method of embodiment 20 that comprises use of an antibody conjugate comprising an antibody that binds to the macrophage marker CD 163 on a Giant Cell and the drug inhibitor of telomerase.
Other embodiments are described by the following claims.
References:
1. Jam AG, Elmariah H. BMT for Myelodysplastic Syndrome: When and Where and How. Front Oncol. 2021; 1 1 :771614.
2. Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 201O;l 15(9): 1850-7.
3. da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, et al. Clonal evolution in myelodysplastic syndromes. Nat Commun. 2017;8: 15099.
4. Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet.
20I7;49(2):204-12.
5. Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci US A 2014;l l l(9):3514-9.
6. Mirzayans R, Andrais B, Murray D. Roles of Polyploid/Multinucleated Giant Cancer Cells in Metastasis and Disease Relapse Following Anticancer Treatment. Cancers (Basel).20I8; 10(4).
7. Mirzayans R, Andrais B, Scott A, Wang YW, Kumar P, Murray D. Multinucleated Giant Cancer Cells Produced in Response to Ionizing Radiation Retain Viability and Replicate Their Genome. Int J Mol Sci. 2017; 18(2).
8. Ohashi R, Hayama A, Matsubara M, Watarai Y, Sakatani T, Naito Z, et al. Breast carcinoma with osteociast-like giant cells: A cytological-pathological correlation with a literature review. AnnDiagnPathol. 2018;33:1-5.
9. Pienta KJ, Hammarlund EU, Axelrod R, Brown JS, Amend SR. Poly-aneuploid cancer cells promote evolvability, generating lethal cancer. Evol Appl. 2020; 13(7): 1626-34.
10. Pienta KJ, Hammarlund EU, Brown JS, Amend SR, Axelrod RM. Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proc Natl Acad Sci U S A 2021 ; 118(7).
11. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002;21 (4):674-9.
Claims
1. A method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject a composition targeting a telomerase in a Giant Cell of the blood disorder.
2. The method of claim 1, wherein the blood disorder is Myelodysplastic syndromes (MDS).
3. The method of claim 1, wherein the blood disorder is acute myeloid leukemia (AML).
4. The method of claim 1, wherein the composition comprises a telomerase-specific antisense oligonucleotide.
5. The method of claim 4, wherein the telomerase-specific antisense oligonucleotide is Imetelstat.
6. The method of claim 1, wherein the composition comprises a molecule specific for an antigen on the Giant Cell, wherein the antigen comprises a macrophage marker, and wherein the molecule is conjugated to a telomerase inhibitor. The method of claim 6, wherein the macrophage marker is CD 163.
7. The method of claim 6, wherein the telomerase inhibitor is a telomerase-specific antisense oligonucleotide.
8. The method of claim 7, wherein the telomerase-specific antisense oligonucleotide is Imetelstat.
9. The method of claim 6, wherein the telomerase inhibitor is a small molecule inhibitor.
10. The method of claim 9, wherein the small molecule inhibitor is BIBRI 532.
11. The method of claim 6, wherein the molecule is an antibody specific for a macrophage marker.
12. The method of claim 6, wherein the molecule is an antibody specific for CD 163.
13. The method of claim 1, wherein the composition comprises a small molecule inhibitor of the telomerase.
14. The method of claim 13, wherein the small molecule inhibitor is BIBRI 532.
15. The method of any one of claims 1-14, further comprising detecting or isolating a Giant Cell from the subject with Blood Disorder prior to administering a composition; wherein the Giant Cell expresses telomerase.
16. The method of claim 15, wherein the composition comprises a telomerase-specific antisense oligonucleotide.
17. The method of claim 16, wherein the telomerase-specific antisense oligonucleotide is Imetelstat.
18. The method of claim 15, wherein the composition comprises a molecule specific for an antigen on the Giant Cell, wherein the antigen comprises a macrophage marker, and wherein the molecule is conjugated to a telomerase inhibitor.
19. The method of claim 18, wherein the macrophage marker is CD163.
20. The method of claim 18, wherein the telomerase inhibitor is a telomerase-specific antisense oligonucleotide.
21. The method of claim 20, wherein the telomerase-specific antisense oligonucleotide is Imetelstat.
22. The method of claim 18, wherein the telomerase inhibitor is a small molecule inhibitor.
23. The method of claim 22, wherein the small molecule inhibitor is BIBRI 532.
24. The method of claim 18, wherein the molecule is an antibody specific for a macrophage marker.
25. The method of claim 18, wherein the molecule is an antibody specific for CD 163.
26. The method of claim 15, wherein the composition comprises a small molecule inhibitor of the telomerase.
27. The method of claim 26, wherein the small molecule inhibitor is BIBRI 532.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363508087P | 2023-06-14 | 2023-06-14 | |
| US63/508,087 | 2023-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024259369A1 true WO2024259369A1 (en) | 2024-12-19 |
Family
ID=91946388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2024/034194 WO2024259369A1 (en) | 2023-06-14 | 2024-06-14 | Compositions targeting giant cells in blood disorders |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024259369A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014088785A1 (en) * | 2012-12-07 | 2014-06-12 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
-
2024
- 2024-06-14 WO PCT/US2024/034194 patent/WO2024259369A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014088785A1 (en) * | 2012-12-07 | 2014-06-12 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
Non-Patent Citations (18)
| Title |
|---|
| ADAMS DLMARTIN SSALPAUGH RKCHARPENTIER MTSAI SBERGAN RC ET AL.: "Circulating giant macrophages as a potential biomarker of solid tumors", PROC NATL ACAD SCI US A, vol. 111, no. 9, 2014, pages 3514 - 9, XP055248775, DOI: 10.1073/pnas.1320198111 |
| ALLEGRA ALESSANDRO ET AL: "Telomerase and telomere biology in hematological diseases: A new therapeutic target", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 56, 7 February 2017 (2017-02-07), pages 60 - 74, XP029951054, ISSN: 0145-2126, DOI: 10.1016/J.LEUKRES.2017.02.002 * |
| ANONYMOUS: "FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia", 6 June 2024 (2024-06-06), XP093202456, Retrieved from the Internet <URL:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent> [retrieved on 20240906] * |
| BARWE S P ET AL: "Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts", JOURNAL OF CLINICAL MEDICINE, vol. 11, no. 7, 30 March 2022 (2022-03-30), CH, pages 1923, XP093202343, ISSN: 2077-0383, DOI: 10.3390/jcm11071923 * |
| DA SILVA-COELHO PKROEZE LIYOSHIDA KKOORENHOF-SCHEELE TNKNOPS RVAN DE LOCHT LT ET AL.: "Clonal evolution in myelodysplastic syndromes", NAT COMMUN., vol. 8, 2017, pages 15099 |
| HESHAM EL-DALY ET AL: "Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532", BLOOD, vol. 105, no. 4, 1 January 2005 (2005-01-01), pages 1742 - 1749, XP055254432, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/bloodjournal/105/4/1742.full.pdf> [retrieved on 20160302], DOI: 10.1182/blood-2003-12-4322 * |
| JAIN AGELMARIAH H: "BMT for Myelodysplastic Syndrome: When and Where and How", FRONT ONCOL., vol. 11, 2021, pages 771614 |
| LITZOW MRTARIMA SPEREZ WSBOLWELL BJCAIRO MSCAMITTA BM ET AL.: "Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia", BLOOD, vol. 115, no. 9, 2010, pages 1850 - 7 |
| MAKISHIMA HYOSHIZATO TYOSHIDA KSEKERES MARADIVOYEVITCH TSUZUKI H ET AL.: "Dynamics of clonal evolution in myelodysplastic syndromes", NAT GENET., vol. 49, no. 2, 2017, pages 204 - 12 |
| MIRZAYANS RANDRAIS BMURRAY D: "Roles of PolyploidiMultinucleated Giant Cancer Cells in Metastasis and Disease Relapse Following Anticancer Treatment", CANCERS, vol. 10, no. 4, 2018 |
| MIRZAYANS RANDRAIS BSCOTT AWANG YWKUMAR PMURRAY D: "Multinucleated Giant Cancer Cells Produced in Response to Ionizing Radiation Retain Viability and Replicate Their Genome", INT J MOL SCI, vol. 18, no. 2, 2017 |
| OHASHI RHAYAMA AMATSUBARA MWATARAI YSAKATANI TNAITO Z ET AL.: "Breast carcinoma with osteoclast-like giant cells: A cytological-pathological correlation with a literature review", ANNDIAGNPATHOL, vol. 33, 2018, pages 1 - 5 |
| PIENTA KJHAMMARLUND EUAXELROD RBROWN JSAMEND SR: "Poly-aneuploid cancer cells promote evolvability, generating lethal cancer", EVOL APPL, vol. 13, no. 7, 2020, pages 1626 - 34 |
| PIENTA KJHAMMARLUND EUBROWN JSAMEND SRAXELROD RM: "Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells", PROC NATL ACAD SCI U S A, vol. 118, no. 7, 2021 |
| VONDERHEIDE RH: "Telomerase as a universal tumor-associated antigen for cancer immunotherapy", ONCOGENE, vol. 21, no. 4, 2002, pages 674 - 9, XP037737630, DOI: 10.1038/sj.onc.1205074 |
| YANG FEIFEI ET AL: "Characteristics of macrophages from myelodysplastic syndrome microenvironment", EXPERIMENTAL CELL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 408, no. 1, 112837, 20 September 2021 (2021-09-20), XP086827979, ISSN: 0014-4827, [retrieved on 20210920], DOI: 10.1016/J.YEXCR.2021.112837 * |
| YEH TSUNG-JANG ET AL: "Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer", BIOMEDICINES, vol. 11, no. 3, 24 February 2023 (2023-02-24), Basel, pages 691, XP093202335, ISSN: 2227-9059, DOI: 10.3390/biomedicines11030691 * |
| ZEIDAN AMER METHQAL ET AL: "7004 - IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).", J. CLIN. ONCOL. 2023 ASCO ANNUAL MEETING I : HEMATOLOGIC MALIGNANCIES-LEUKEMIA, MYELODYSPLASTIC SYNDROMES, AND ALLOTRANSPLANT, vol. 41, no. 16 (Suppl.), 31 May 2023 (2023-05-31), pages 7004, XP093202342, DOI: 10.1200/JCO.2023.41.16_suppl.7004 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mondini et al. | Radiotherapy–immunotherapy combinations–perspectives and challenges | |
| Tong et al. | ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma | |
| Farren et al. | Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy | |
| Stoyanov et al. | On the concepts and history of glioblastoma multiforme—morphology, genetics and epigenetics | |
| Le et al. | Current treatment landscape of nasopharyngeal carcinoma and potential trials evaluating the value of immunotherapy | |
| Boeckman et al. | Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining | |
| Ward et al. | Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51 | |
| Nieborowska-Skorska et al. | Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells | |
| Kavanagh et al. | DNA double strand break repair: a radiation perspective | |
| Ogiwara et al. | Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor | |
| Karagiannis et al. | Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments | |
| Hotte et al. | A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer: Canadian cancer trials group study IND205 | |
| Makise et al. | H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features | |
| Qu et al. | Biological effects of 125 I seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death | |
| Goedegebuure et al. | Interferon-and STING-independent induction of type I interferon stimulated genes during fractionated irradiation | |
| Eyre et al. | A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL | |
| Wang et al. | Antitumor effect of anti‐c‐Myc aptamer‐based PROTAC for degradation of the c‐Myc protein | |
| Bui et al. | ARID1A‐SIN3A drives retinoic acid‐induced neuroblastoma differentiation by transcriptional repression of TERT | |
| US20090214420A1 (en) | Method of Diagnosis and Treatment and Agents Useful for Same | |
| Istiqomah et al. | Anticancer effects of polyisoprenoid from Nypa fruticans leaves by controlling expression of p53, EGFR, PI3K, AKT1, and mTOR genes in colon cancer (WiDr) cells | |
| Mukherjee et al. | Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression | |
| JP2016538883A (en) | Oxidative fraction of extracellular DNA as a biomarker of stress and method of use thereof | |
| Jiang et al. | Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice | |
| Zhu et al. | Low‐intensity pulsed ultrasound alleviates doxorubicin‐induced cardiotoxicity via inhibition of S100a8/a9‐mediated cardiac recruitment of neutrophils | |
| Gordon et al. | Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: an open label, phase 2 study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24742725 Country of ref document: EP Kind code of ref document: A1 |